This data suggests that either lowering overexpression or inhibiting activity of MYO1D could have therapeutic potential in a subtype of CRC with high expression of EGFR family members and could also help to overcome tumor resistance to anti-EGFR therapy. The gene discussed is EGFR; the disease is colorectal carcinoma.